COMPOSITION PHARMACEUTIQUE CONTENANT UN COMPOSANT D'INDUCTION D'ACTIVATION DE LA PROTÉINE TAZ POUR DIFFÉRENCIATION MUSCULAIRE ET RÉGÉNÉRATION MUSCULAIRE
The present invention relates to a composition containing TM-53 and TM-54 as an active ingredient for inducing or promoting myocyte differentiation, a pharmaceutical composition for muscle regeneration, and a pharmaceutical composition for treating or preventing muscle dystrophy. More specifically, 2-butyl-styryl-1-[2'-(1H-tetrazole-5-yl)-bisphenyl-4-ylmethyl]-1H-benzoimidazole-5-carboxylic acid methylester(2-butyl-6-styryl-1-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1H-benzoimidazole-5-carboxylic acid methyl ester, TM-53) or 2-butyl-5-styryl-1-[2'-(1H-tetrazole-5-yl)-bisphenyl-4-ylmethyl]-1H-benzoimidazole-5-carboxylic acid methylester(2-butyl-5-styryl-1-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1H-benzoimidazole-6-carboxylic acid methyl ester, TM-54) promotes differentiation and transdifferentiation into myocytes from myoblasts and non-myoblasts depending on TAZ protein in vitro, increases the expression of myogenic marker protein while reducing the expression of myoatrophy related genes in myocytes treated with a myoatrophy inducing material, and significantly exhibits a muscle generation effect in the muscle damage model in vivo, and thus can be favorably used as an active ingredient of a composition for inducing or promoting myocyte differentiation, a pharmaceutical composition for muscle generation, and a pharmaceutical composition for treating or preventing muscle dystrophy.La présente invention concerne une composition contenant TM-53 et TM-54 en tant que substance active pour induire ou stimuler la différenciation de myocytes, une composition pharmaceutique pour la régénération musculaire, et une composition pharmaceutique pour traiter ou prévenir une dystrophie musculaire. Plus spécifiquement, l'ester méthylique d'acide 2-butyl-styryl-1-[2'-(1H-tétrazole-5-yl)-bisphényl-4-ylméthyl]-1H-benzoimidazole-5-carboxylique (ester méthylique d'acide (2-butyl-6-styryl-1-[2'-(1H-tétrazol-5-yl)-biphényl-4-ylméthyl]-1H-benzoimidazole-5-carboxylique, TM-53) ou l'este
